Copyright: ©Author(s) 2026.
World J Clin Cases. Mar 26, 2026; 14(9): 118187
Published online Mar 26, 2026. doi: 10.12998/wjcc.v14.i9.118187
Published online Mar 26, 2026. doi: 10.12998/wjcc.v14.i9.118187
Table 3 Baseline characteristics of the patients who developed post-immune checkpoint inhibitors cardiac complications (n = 14), n (%)
| Characteristic | Value |
| Median age, years (IQR) | 59.5 (54-64) |
| Gender | |
| Male | 11 (78.6) |
| Female | 3 (21.4) |
| Nationality | |
| Filipino | 3 (21.4) |
| Jordanian | 3 (21.4) |
| Syrian | 2 (14.3) |
| Bahraini | 1 (7.1) |
| Bangladeshi | 1 (7.1) |
| Egyptian | 1 (7.1) |
| Indian | 1 (7.1) |
| Palestinian | 1 (7.1) |
| Qatari | 1 (7.1) |
| Comorbidities | |
| Hypertension | 9 (64.3) |
| Dyslipidemia | 7 (50.0) |
| Chronic kidney disease | 6 (42.9) |
| Type 2 diabetes | 5 (35.7) |
| Smoking | 4 (28.6) |
| Ischemic heart disease | 3 (21.4) |
| Hypothyroidism | 2 (14.3) |
| Type 1 diabetes | 1 (7.1) |
| Stroke | 1 (7.1) |
| Chronic heart failure | 1 (7.1) |
| Peripheral vascular disease | 1 (7.1) |
| Previous cardiomyopathy | 1 (7.1) |
| Previous arrhythmia | 1 (7.1) |
| Type of ICI administered | |
| Pembrolizumab | 11 (78.6) |
| Atezolizumab | 2 (14.3) |
| Nivolumab | 1 (7.1) |
- Citation: Chapra A, Ata F, Abdellatif A, Nofal M, Daniyal A, Mohammad Younus A, Shah JZ, Rasul K. Incidence and clinical course of immune checkpoint inhibitor-related cardiac adverse events: A descriptive study from the Middle East. World J Clin Cases 2026; 14(9): 118187
- URL: https://www.wjgnet.com/2307-8960/full/v14/i9/118187.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v14.i9.118187